Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal iloprost
- Development stage
- Unknown
- Lead developer
- Liquidia
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Inhalation
01
Overview
Liposomal iloprost (also known as L606) is an inhaled, extended-release formulation of the prostacyclin analog iloprost, developed by Pharmosa Biopharm. It utilizes a proprietary liposomal delivery system to encapsulate the active drug, which significantly extends its plasma half-life to over 3 hours, compared to the 20-30 minutes observed with conventional inhaled iloprost (Ventavis). This pharmacokinetic profile supports twice-daily dosing and potential self-administration at home, offering a more convenient alternative to continuous intravenous iloprost infusions. The drug is currently in Phase 3 development for pulmonary arterial hypertension (PAH) and Phase 1 for systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
- Other names
- inhaled liposomal iloprost
02
Targets
PTGIR (Prostanoid IP Receptor)PTGER3 (Prostaglandin E2 receptor EP3 subtype)PTGER1 (Prostaglandin E Receptor 1)
Beyond the preview
Go deeper on liposomal iloprost.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal iloprost.